{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-032453","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.234600+00:00","generated_at":"2026-05-31T09:02:36.051262+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vivos Therapeutics Q2 revenue up 19% YoY to $4.1M; operating expenses down 31%","bullets":["Revenue $4.1M vs $3.4M YoY; gross margin improved to 65% from 62%.","Operating loss reduced 57% YoY; eight straight quarters of YoY expense cuts.","Cash $6.9M; stockholders' equity $6.3M; expects positive cash flow in early 2025.","Received Medicare reimbursement for CARE oral devices; closed $7.5M equity investment from New Seneca Partners.","New strategic alliance with sleep testing centers in Colorado; pilot showed 79% of patients chose Vivos therapy over CPAP."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-032453","json":"https://secwatch.observer/filing/0001493152-24-032453.json","markdown":"https://secwatch.observer/filing/0001493152-24-032453.md","text":"https://secwatch.observer/filing/0001493152-24-032453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224032453/0001493152-24-032453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224032453/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:02:36.051262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}